Victrex Target Stock Price Drops

Spinal Tech

Victrex had its target stock price cut from $21.48 per share to $21.33 by Bank of America research analysts. The stock has been rated “underperform.” Analysts from the Jefferies Group have said to “hold” on purchasing the company’s stock, while JPMorgan Chase gave it a “neutral” rating.

Victrex works with manufacturing of high performance polymers through its two business units, Invibio Biomaterial Solutions and Victrex Polymer Solutions.

More Articles on Devices:
MAKO Surgical Settles Lawsuit, Acquires Stanmore Robotic Assets
Stryker Releases Spine Screw, Surgical Devices
Sonoma Orthopedic Products Develops Minimally Invasive Technique For Fractures

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like